ArticlePathophysiology : the official journal of the International Society for Pathophysiology2014
Heparin-binding EGF-like growth factor (HB-EGF) therapy for intestinal injury: Application and future prospects.
Article in Pathophysiology : the official journal of the International Society for Pathophysiology, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed, 25 citations in OpenAlex.
- Brainstem microglial cell morphology in neonatal rats with necrotizing enterocolitis and the effects of prenatal heparin-binding epidermal growth factor-like growth factor.World journal of pediatric surgery · 2025Article
- Necrotizing enterocolitis: current understanding of the prevention and management.Pediatric surgery international · 2024Review
- Shaping infant development from the inside out: Bioactive factors in human milk.Seminars in perinatology · 2023Review
- Potentially functional variants of HBEGF and ITPR3 in GnRH signaling pathway genes predict survival of non-small cell lung cancer patients.Translational research : the journal of laboratory and clinical medicine · 2021Article
- Locally administered heparin-binding epidermal growth factor-like growth factor reduces radiation-induced oral mucositis in mice.Scientific reports · 2020Article
- Eckol Alleviates Intestinal Dysfunction during Suckling-to-Weaning Transition via Modulation of PDX1 and HBEGF.International journal of molecular sciences · 2020Article
- Epidermal growth factor as a reliable marker of necrotizing enterocolitis in preterm neonates.Clinical and experimental pediatrics · 2020Article
- Necrotizing enterocolitis: It's not all in the gut.Experimental biology and medicine (Maywood, N.J.) · 2020Review
- A Review of the Immunomodulating Components of Maternal Breast Milk and Protection Against Necrotizing Enterocolitis.Nutrients · 2019Review
- New insights into necrotizing enterocolitis: From laboratory observation to personalized prevention and treatment.Journal of pediatric surgery · 2019Review
- Roles for HB-EGF in Mesenchymal Stromal Cell Proliferation and Differentiation During Skeletal Growth.Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research · 2019Article
- [Research advances in necrotizing enterocolitis in neonates].Zhongguo dang dai er ke za zhi = Chinese journal of contemporary pediatrics · 2018Review
- The Role of Mucosal Immunity in the Pathogenesis of Necrotizing Enterocolitis.Frontiers in pediatrics · 2017Review
- Necrotizing enterocolitis: new insights into pathogenesis and mechanisms.Nature reviews. Gastroenterology & hepatology · 2016Review
- No systemic exposure of transtympanic heparin-binding epidermal growth factor like growth factor.Drug and chemical toxicology · 2016Article
- Heparin-binding EGF-like growth factor and enteric neural stem cell transplantation in the prevention of experimental necrotizing enterocolitis in mice.Pediatric research · 2015Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 2 institutions in 1 country.
Funding
Abstract
Throughout the past 20 years, we have been investigating the potential therapeutic roles of heparin-binding EGF-like growth factor (HB-EGF), a member of the epidermal growth factor family, in various models of intestinal injury including necrotizing enterocolitis (NEC), intestinal ischemia/reperfusion (I/R) injury, and hemorrhagic shock and resuscitation (HS/R). Our studies have demonstrated that HB-EGF acts as an effective mitogen, a restitution-inducing reagent, a cellular trophic factor, an anti-apoptotic protein and a vasodilator, via its effects on various cell types in the intestine. In the current paper, we have reviewed the application and therapeutic effects of HB-EGF in three classic animal models of intestinal injury, with particular emphasis on its protection of the intestines from NEC. Additionally, we have summarized the protective functions of HB-EGF on various target cells in the intestine. Lastly, we have provided a brief discussion focusing on the future development of HB-EGF clinical applications for the treatment of various forms of intestinal injury including NEC.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.